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Mutations in the mismatch repair genes cause Lynch syndrome (LS), conferring high risk of colorectal, endometrial and some
other cancers. After the same splice site mutation in the MLH1 gene (c.589-2A>G) had been observed in four ostensibly
unrelated American families with typical LS cancers, its occurrence in comprehensive series of LS cases (Mayo Clinic, Germany
and Italy) was determined. It occurred in 10 out of 995 LS mutation carriers (1.0%) diagnosed in the Mayo Clinic diagnostic
laboratory. It did not occur among 1,803 cases tested for MLH1 mutations by the German HNPCC consortium, while it
occurred in three probands and an additional five family members diagnosed in Italy. In the U.S., the splice site mutation
occurs on a large (~4.8 Mb) shared haplotype that also harbors the variant c.2146G>A, which predicts a missense change in
codon 716 referred to here as V716M. In Italy, it occurs on a different, shorter shared haplotype (~2.2 Mb) that does not
carry V716M. The V716M variant was found to be present by itself in the U.S., German and Italian populations with
individuals sharing a common haplotype of 280 kb, allowing us to calculate that the variant arose around 5,600 years ago
(225 generations; 95% confidence interval 183–272). The splice site mutation in America arose or was introduced some 450
years ago (18 generations; 95% confidence interval 14–23); it accounts for 1.0% all LS in the Unites States and can be
readily screened for.
Germline mutations that occur in more than one or just a
few individuals are of two distinct types. The ﬁrst type, here
referred to as ‘‘recurrent’’ arises repeatedly de novo, usually
because of a sequence peculiarity that predisposes to an
abnormal event at meiosis. The second type, referred to here
as a ‘‘founder’’ mutation, arose in a single ancestor and is
subsequently inherited by numerous descendants.
Lynch syndrome (LS), previously known as hereditary
nonpolyposis colorectal cancer (HNPCC), is caused by germ-
line mutations in the mismatch repair genes MSH2, MLH1,
MSH6 and PMS2. LS is characterized by an extremely high
risk of colorectal and endometrial cancer and to a lesser
degree, several other cancers. Both recurrent and founder
mutations in the mismatch repair genes have been amply
described. As an example, a prototype recurrent mutation in
MSH2 is an A to T transversion in the third nucleotide of
the donor splice site of intron 5 (abbreviated c.942þ3A>T)
leading to the skipping of exon 5 resulting in loss of MSH2
function. The sequence peculiarity predisposing to this recur-
rent mutation is apparently the fact that the mutated A is the
ﬁrst of a tract of 26 adenines, which predisposes to misalign-
ment during meiotic pairing.1,2 This recurrent mutation
occurs worldwide and accounts for 5–10% of all MSH2 muta-
tions. A prototype LS founder mutation is the c.1906G>C
transversion in MSH2 that leads to a missense amino acid
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substitution of alanine to proline, A632P.3 As is the case with
many founder mutations, this mutation occurs only in one
ethnic population, in this case the Ashkenazi Jews, where it
may account for approximately one-third of all LS cases.3
Recurrent and founder mutations are medically important
because they can facilitate diagnostic approaches. In popula-
tions where they occur with appreciable frequency, mutation
testing can begin by a simple test for the main recurrent or
founder mutations. If a mutation is found, further testing can
be avoided thus resulting in cost savings. Founder mutations
typically occur in isolated, ethnically distinct populations.
The U.S. population is ethnically heterogeneous; therefore
widespread founder mutations are not common. A remark-
able exception is the deletion of exons 1–6 of the MSH2 gene
that is referred to as the American Founder Mutation.4–6 In
this communication, we describe a splice site mutation in
MLH1. We show that this mutation is relatively common in
the U.S. where it either arose in or was brought in by an
early immigrant. Moreover, we show that the mutation
occurred in an allele that already carried another more com-
mon founder sequence change in MLH1 (missense variant
V716M) so that the mutated allele contains both changes.
We discuss the implications of these ﬁndings.
Material and Methods
Study samples
Our study included cases from Italy, Germany and the
United States carrying either the deleterious MLH1 splice site
mutation (c.589-2A>G) or the innocent MLH1 V716M vari-
ant or both. Informed consent, approved by our respective
Institutional Review Boards to conduct genetic experiments,
was obtained from the study subjects.
The Italian samples belonged to families A-AV23 and A-
AV447 and A-AV24.8 The newly acquired probands for fami-
lies A-TN5 and A-TN6 were selected in Presidio Ospedaliero
Santa Chiara in Trento (Italy) and sent to Centro Riferi-
mento Oncologico in Aviano for genetic testing.
The German cases were counseled and underwent genetic
testing at the facilities of the German HNPCC-Consortium as
described elsewhere.9 They were then entered into the Ger-
man mutation database.
The ﬁrst description of the splice site mutation was in a
colorectal cancer patient.10 We have studied North American
samples from Boston,11 Ohio,12 Michigan and the Mayo
Clinic Molecular Diagnostic Laboratory. Since the Mayo
Clinic is a major reference laboratory in the U.S., the samples
obtained from them were from patients undergoing clinical
genetic testing for LS from around the U.S. These samples
were anonymized to retain conﬁdentiality. The Michigan
family was identiﬁed in a clinical series tested at the Univer-
sity of Michigan Cancer Genetics Clinic.
Controls genotyped for haplotype analysis were Caucasian
(n ¼ 78) and African American (n ¼ 6) from the Ohio State
University Medical Center’s Human Genetics Sample Bank.
They are derived from the Columbus-area population. This
collection of control samples is approved by the Biomedical
Sciences Institutional Review Board at Ohio State University
Medical Center.
Haplotype analysis
To characterize the haplotypes associated with the MLH1
splice site and V716M changes we used 14 out of 15 micro-
satellite markers previously reported13 that span the MLH1
locus. We added three additional single nucleotide polymor-
phisms (SNPs) present in the MLH1 gene. All available pro-
bands and family members and 84 controls were typed for
these MLH1 markers.
Microsatellite markers were typed utilizing a labeled M13
primer in conjunction with an M13-tailed, amplicon speciﬁc,
primer in a three primer PCR. Each 15-ll PCR reaction con-
tained 7.5 ll of AmpliTaq Gold master mix (PE Applied Bio-
systems, Foster City, CA), 25 ng of genomic DNA, 10 pmol
of untailed primer, 5 pmol of M13-tailed primer and 10
pmol of the FAM-labeled M13 primer. Reactions were cycled
using the following proﬁle: 96C for 10 min, 36 cycles of
96C for 30 sec, 58C for 30 sec, 72C for 30 sec, and ﬁnal
extension at 72C for 5 min. The PCR product was sized
using an ABI 3730 DNA Analyzer.
For the genotyping of SNPs, we used the same PCR con-
ditions as above in the presence of 10 pmol forward and
reverse primers. The PCR product containing the SNP was
subjected to the SNaPshot reaction (PE Applied Biosystems,
Foster City, CA). The sequences for the primers are listed in
Supporting Information Table 1.
Estimating the age of the variants
The DMLEþ2.3 software developed by Reeve and Rannala14
was used to estimate the age of the two variants. The pro-
gram, which is freely available from www.dmle.org, uses a
Bayesian approach to compare differences in linkage disequi-
librium between the mutation and ﬂanking markers, among
DNA samples from mutation carriers and unrelated controls.
This software uses genotype data for cases and controls,
marker locations, population growth rates and an estimate of
the proportion of the mutation bearing chromosomes being
analyzed.
Marker locations were obtained from the human genome
reference sequence (Human build 37.2). The deCODE genetic
positions were known for most of the microsatellite markers.
For the markers and SNPs not in the deCODE map, genetic
distances were obtained with spline interpolation using
known genetic positions of adjacent deCODE markers.
The age of the V716M variant in Europeans was calcu-
lated using German (n ¼ 13) and Italian (n ¼ 2) probands.
For the population growth rate we used 1.05 fold per genera-
tion.15,16 We have estimated the number of the V716M vari-
ant bearing chromosomes for the Italian and German popu-
lations using the frequency of the variant found in the
samples tested, assuming that an innocent variant should
have a similar frequency in controls as in cases. Based on the
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population sizes (Italy  60 million, Germany  82 million)
the numbers of chromosomes were 402,791 and 907,399,
respectively.
The age of the splice site mutation in the American popu-
lation was calculated using a growth rate of 1.65 fold.6 To
estimate the proportion of disease bearing chromosomes
studied, we used the following data: 5.5% lifetime risk for
CRC; 2.8% of CRCs are LS and 1.0% of LS cases are due to
this splice site mutation.
Additionally, we applied the Estiage program17 to estimate
the age of the most recent common ancestor carrying the
V716M variant, since the shared haplotype is relatively small
(280 kb), and it has been densely genotyped. We were unable
to use the same method for the estimation of the most recent
common ancestor carrying the splice site mutation. The
shared haplotype is 17-fold longer (4.8 Mb) and the
number of markers used increases only from 5 to 15, result-
ing in signiﬁcant distances between the markers that is not
suitable for the program.17
Results and Discussion
The MLH1 intron 7 splice site mutation
The c.589-2A>G mutation, ﬁrst published by Luce et al.,10
disrupts the acceptor splice site of intron 7 and results in the
skipping of exon 8. This predicts loss of MLH1 function and
LS, both of which are amply conﬁrmed by the data presented
here. This mutation is one of several hundred different
MLH1 mutations that are known today based on two major
databases (www.insight-group.org/mutation; http://
www.med.mun.ca/mmrvariants/). Subsequently Syngal et al.11
found the same mutation in a LS proband of a family that
met the Amsterdam I criteria.
We found the splice site mutation in the proband of a
large LS family identiﬁed in Ohio. The proband was enrolled
in a population-based study of LS in 563 unselected newly
diagnosed patients with endometrial cancer of whom 14 had
LS (Refs. 12,18 and unpublished data). To assess the propor-
tion of cases carrying the splice site mutation in the Ohio se-
ries, we can use additional data from a study of LS in 1,566
consecutive colorectal cancer patients, of whom 44 had LS.19
Thus, the prevalence of the splice site mutation among pro-
bands with LS is 1/58 or 1.7%. The mutation occurs in six
further members of the Ohio family, four of whom have
been diagnosed with LS cancer. Of note, the splice site muta-
tion is not mentioned in the original reports12,19 because it
was not called by the sequencing software and missed when
the testing was ﬁrst performed and was only recognized later
in a collaboration with and thanks to our colleagues in Ger-
many. Instead, the V716M missense variant was originally
found in the proband and those family members in whom
the splice site mutation was later detected (Pedigree in the
Supporting Information Fig. 3). To conclusively show that
the splice site mutation and the V716M variant were on the
same chromosome, we used the method of conversion to
haploidy20 conﬁrming that the two changes are in cis (see
Supporting Information for description). We thus had evi-
dence of the splice site mutation in three US families; a
fourth family was communicated to us by Dr. Gruber, and it
appeared that the proportion of all LS having the splice site
mutation might be high enough to warrant further investiga-
tion. In our study, it was of interest to answer two questions.
First, how common is the mutation in the US and elsewhere?
Second, is it recurrent or of founder type?
Disease causing mutations are usually too rare to search
for in the general population. Instead it is meaningful to ask
how common the mutation is among LS probands. The data
from individual laboratories are almost never extensive
enough for this purpose, so we turned to three larger sources,
the molecular diagnostic laboratory of the Mayo Clinic, the
German HNPCC consortium and a collaborative group in
Italy. Italy was studied because reports of the mutation had
been published.8,21
The archives of a large molecular diagnostic laboratory
(the Mayo Clinic) were searched for the splice site mutation.
It had been seen in totally 10 individuals, 8 of whom were
ostensibly unrelated, likely representing different families.
During the same time period, a total of 995 cases with LS
had been diagnosed in this laboratory. Thus, the proportion
of carriers of the splice site mutation in the US was 1.0%
(10/995), but none was found in Germany. While it is clearly
desirable to study further cohorts from various geographic
regions, we hypothesize that the mutation is indeed rare in
most other populations than the US and Italy because it has
not been reported to the databases quoted above. In total, we
are presently aware of 22 individuals carrying the splice site
mutation in the US (Table 1).
The MLH1 exon 19 missense variant
In the splice site mutation carrier, Syngal et al.11 noted the
presence of the V716M variant in exon 19, termed missense
mutation, caused by the c.2146G>A sequence change. This
change has been reported numerous times in smaller and
larger series of patients tested for LS. For instance, the
INSiGHT database (www.insight-group.org/mutations) states
that it has been ‘‘cited 58 times’’ but due to double reporting
the real number may be smaller. The amino acid in position
716 is only weakly conserved among species but resides in
the MLH1 domain that binds PMS2. The wild type amino
acid, valine is neutral and hydrophobic while methionine is
also hydrophobic, but contains sulfur.
Typically, missense mutations can be either deleterious or
nondeleterious, and it is almost impossible to predict the
pathogenicity of missense changes based solely on the func-
tional domain and the nature of the amino acids involved.
Several groups of investigators have used a variety of strat-
egies to investigate the variant’s effect on mismatch repair.
Raevaara et al.22 examined protein expression, stability, sub-
cellular localization, PMS2 interaction and mismatch repair
efﬁciency and concluded that V716M is functionally normal.
The same result emerged from functional assays in yeast,23,24
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from a cell free complementation assay25 and from a recent
study combining several methods.26 Thus, ample functional
evidence strongly suggests that V716M does not affect mis-
match repair.
Existing evidence from the case-report type publications
points in the same direction. V716M has been reported
numerous times, but it is not well established how many cases
totally were studied for MLH1. In the Mayo Clinic series,
V716M (without the splice site mutation) occurred in at least
7 individuals out of 1,385 in whom MLH1 was studied for
mutation (~0.5%). In the German series, 20 V716M carriers
were found among 1,803 patients in whom MLH1 was studied
(1.1%). Several authors report having searched for V716M in
controls and no V716M mutation carriers were found in a
total of some 400 controls reported in these studies.12,26–28 In
a study of primary antibody deﬁciency syndromes in Swe-
den,29 991 control individuals were tested for V716M. The al-
lele frequency was 3/1904 (i.e., a carrier frequency of approxi-
mately 3/952, 0.3%). In a comprehensive study by Barnetson
et al.,30 the V716M variant was considered to be benign based
on a variety of functional criteria. It was seen in 1/932 (0.1%)
colorectal cancer patients and in 6/1,000 (0.6%) controls.
Thus, in summary, the proportion of V716M carriers in
patients studied for LS (~0.8%) appears to be similar to the
Table 1. Clinical features of c.589–2A>G mutation carriers
Case Gender Age1 Cancer History2 Relationship
U.S. Cases
CGN 6291–00 Female 50 EC;48, Ovarian;48 Proband
1229–01.SV Female 50 EC;39 Proband
1229–02.BV Female 75 CRC;41, EC;63 Mother
1229–04.NV Female 48 Unaffected Sister
1229–07.2JV Male 31 Unaffected Son
1229–11.2PS Male 72 Urothelial;60 Maternal Uncle
1229–25.1MS Male d.43 Small bowel;41 Maternal ﬁrst cousin (son of 1229–11.2PS)
1229–11.1MS Male d.51 8–10 Colon polyps Maternal Uncle
1229–24.1LH Female 40 CRC;28 Maternal ﬁrst cousin (daughter of 1229–11.3MS)
Mayo 3 Female 42 EC; by 42, CRC by 42; Ovarian by 42 Proband
Mayo 4 Female 48 EC; 48 Proband
Mayo 5 Male 37 CRC; by 37 Proband
Mayo 8 Male 50 Synchronous CRC; 45 Proband
Mayo 9 Male 33 Unaffected Son of proband (not tested at Mayo)
Mayo 10 Female 65 CRC; age unknown Relative of proband (not tested at Mayo)
Mayo 11 Male 78 CRC; 49, 51, 61 Proband
Mayo 12 Female 53 Endocervical; 45, Lung; 46, CRC; 50 Daughter of Mayo 11
Mayo 13 Female 23 CRC; 19 Granddaughter of Mayo 11
Mayo 14 Male 28 Unaffected Son of proband (not tested at Mayo)
DF 1751 Male d.75 CRC;33, CRC;39, Melanoma;65 Proband
Female d.61 Breast;39, CRC;47, CRC;59 Daughter of DF 1751
Male 54 CRC;53 Son of DF 1751
Italian Cases
CFS1 (A-AV24) Female 70 EC;52 Proband
CFS87 (A-AV24) Male 51 CRC;30 Cousin of CFS1
CFS88 (A-AV24) Female 59 CRC;52, EC;57 Cousin of CFS1
CFS507 (A-AV24) Female 46 EC;44, Ovarian;44 Daughter of CFS1
CFS629 (A-AV24) Female 28 CRC;26 Granddaughter of CFS1 (daughter of CFS507)
CFS728 (A-TN5) Female 63 EC;56, CRC;60 Proband
CFS802 (A-TN6) Female 46 CRC;27, Stomach;43 Proband
CFS803 (A-TN6) Male 64 CRC;56 Brother of CFS802
Abbreviations: CRC, colorectal cancer; EC, endometrial cancer; d, died.
1Current age/Age at death. 2Numbers refer to age at diagnosis. E
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proportion in controls (~0.6%), supporting the notion that the
missense change should be viewed as a harmless polymor-
phism. Our haplotype data (see below) suggest that V716M
is an ancestral founder variant. Such changes are known to
vary in frequency between populations; hence, minor biases
in the choice of cases and controls may underlie the differen-
ces reported.
As quoted above, several extensive studies have now con-
cluded that V716M is clinically innocent. However, at the
time we detected V716M in a young proband with endome-
trial cancer12 and a family history suggesting LS, the benign
nature of V716M had not been deﬁnitively established. After
the patient and her family had been counseled and tested, it
became clear that V716M segregated with the disease in the
family as shown in the pedigree (Supporting Information Fig.
3). Later a more penetrant splice site mutation was found in
one member of the family that had simply been missed when
the proband’s DNA had been sequenced. Given the frequent
association of V716M with the splice site mutation in the
US, we suggest that the sequencing results for intron 7 be
carefully evaluated in individuals displaying V716M.
Haplotype analyses and mutation age estimation
We genotyped 3 SNPs and 14 microsatellite markers in car-
riers of both the splice site mutation and the V716M variant,
and constructed haplotypes by the PHASE method31,32 in
mutation carriers (Fig. 1 and Supporting Information Fig. 2).
Based on data from one individual each from 11 unrelated
American families carrying both sequence changes (Fig. 1a) a
shared haplotype was found which covers a genomic region
of some 4.8 Mb around MLH1. Based on these data the
DMLEþ2.3 program predicts an age of the splice site muta-
tion of some 18 generations, which is the equivalent of
around 450 years (conﬁdence interval 340–585 years) since
founding (Fig. 2a).
Figure 1. Genotype data spanning the MLH1 locus in 33 probands. Haplotypes associated with the mutations are highlighted in gray, with
the mutation allele bolded. (a) US samples with both the splice site mutation and the V716M variant. (b) Italian samples carrying only the
splice site mutation. (c) Italian (1, 2), German (3–15) and US (16–20) samples with the V716M variant. The sizes of the shared haplotypes
are indicated with empty bars below each group. Underlined is the allele associated with the V716M variant in Italian proband 1, which
was determined based on genotyping of 2 relatives of the proband (see Supporting Information Fig. 2). *Frequencies in controls of the
bolded alleles (in a).
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Based on data from one individual in each of the three
Italian families with the splice site mutation (without
V716M) an unequivocally determined shared haplotype (Fig.
1b) suggests a founder mechanism, and the haplotype is
entirely different from that of the American cases (Fig. 1a). It
is also smaller, comprising some 2.2 Mb. These data imply
that the splice site mutation arose at least twice, once in an
early American immigrant (or in an ancestor of an immi-
grant) and once elsewhere (perhaps Italy) a long time ago.
All of the US, Italian and German carriers of V716M
without the splice site change (Fig. 1c) share a short haplo-
type comprising some 280 kb. Importantly, this haplotype is
identical with the central part of the haplotype seen in US
carriers of both the splice site mutation and V716M (Fig.
1a). These haplotypes suggest the possibility that the V716M
in all or most cases represents a single, ancient mutational
event. Moreover, the splice site mutation seen in the US, but
not the one seen in Italy, arose more recently in a chromo-
some carrying the ancestral V716M. Under this assumption
we performed the age calculation for the V716M variant for
the group of Italian and German carriers of the V716M and
the age was estimated to be some 225 generations (95% CI:
183–272) or around 5,600 years (Fig. 2b).
Applying another method, the Estiage program (Ref. 17;
see Material and Methods), we estimated the age of the most
recent common ancestor carrying the V716M variant to be
some 219 generations (95% CI: 152–317). This is similar to
the age of the mutation estimate obtained using DMLEþ2.3
program but with a wider conﬁdence interval. We were not
able to apply the Estiage program to estimate the age of
splice site mutation reliably due to low density of genotyped
markers in the larger shared region (see Material and
Methods).
Examples of other MLH1 founder mutations are the two
described in Finland13,33 that together account for up to 50%
of all LS in Eastern Finland. Another example is the one-base
pair insertion in exon 13 of MLH1 (c.1489_1490insC) which
has been seen frequently in Germany, and a few times in sur-
rounding countries, but not elsewhere. The authors suggested
a founder mutation.34 As the founding of the US mutation is
relatively recent its proportion of all LS is modest. We never-
theless consider it worthwhile to suggest screening cancer
patients with immunohistochemical loss of staining for
MLH1 for the splice site mutation as a ﬁrst or early step in
the mutation detection procedure.
In our study, we estimated the age of both changes.
These estimates tend to have broad margins of error
based on what parameters are used in the calculation (see
Materials and Methods). We are conﬁdent that the age of
the splice site mutation is considerably younger than the
age of the V716M variant based on the size of the shared
haplotype and as a result of mutation age estimation.
However, the age for the innocent variant could be signiﬁ-
cantly younger if the frequency of the mutation in the
population turns out to be smaller (Supporting Informa-
tion Fig. 4).
Finally, it is worth considering whether the presence of
V716M might predispose to the splice site change. Since both
Figure 2. Age estimate for the MLH1 variants. (a) Age estimate for splice site founder mutation in the US population. The posterior
probability distribution plot of the mutation age (in generations), as estimated by the software DMLEþ2.3 is shown when a population
growth rate of 1.65-fold per generation (25 y) is assumed. The dotted lines show the 95% CIs. (b) Age estimate for the V716M variant in
Europeans. The posterior probability distribution plot of the mutation age (in generations), as estimated by the software DMLEþ2.3 is
shown when a population growth rate of 1.05-fold per generation (25 y) is assumed. The dotted lines show the 95% CI.
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changes are rare, the a priori likelihood of them being found
together is small, but the absence of the V716M variant in
Italian cases with the splice site mutation speaks (weakly)
against this hypothesis.
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